Washington, D.C. – The week of June 2, 2025, is poised to be pivotal for the future of United States healthcare funding and policy, with the unveiling of significant proposed budget reductions for the Department of Health and Human Services (HHS) and key legislative battles unfolding on Capitol Hill.
The proposed HHS budget for Fiscal Year (FY) 2026 includes sweeping cuts that would fundamentally alter the landscape of federal health initiatives. Under the proposal, HHS would receive a total allocation of $95 billion. This represents a substantial 25 percent decrease from the FY 2025 funding levels, amounting to a reduction of $31 billion.
Proposed Reorganization and Significant Reductions
A central feature of the proposed budget is the establishment of a new entity, the Administration for a Healthy America (AHA). This administration is envisioned with a budget authority of $14 billion. However, analyses indicate that this figure represents an estimated $6 billion cut compared to the current funding allocated to the various programs that would be consolidated and transferred into the AHA’s purview.
The proposed cuts extend to several of the nation’s most critical health agencies, responsible for everything from biomedical research and disease control to drug safety and healthcare program administration. The National Institutes of Health (NIH), the primary federal agency conducting and supporting medical research, faces the largest proposed reduction. Its budget would be cut by $17 billion, bringing its total funding down to $27.5 billion.
The Centers for Disease Control and Prevention (CDC), the nation’s leading public health agency, is also slated for significant cuts. The proposal includes a $550 million reduction, decreasing the CDC’s budget to $4.1 billion. The Centers for Medicare & Medicaid Services (CMS), which administers vital federal healthcare programs like Medicare and Medicaid, would see its budget authority cut by $673 million, bringing it to $3.5 billion.
Funding for the US Food and Drug Administration (FDA), responsible for safeguarding public health by assuring the safety and security of human and veterinary drugs, biological products, medical devices, the nation’s food supply, cosmetics, and products that emit radiation, would also be substantially reduced. The proposed budget authority for the FDA is marked for a $409 million cut, lowering its funding to $3.1 billion.
Legislative Agenda Takes Center Stage
Concurrent with the budget revelations, legislative efforts addressing healthcare and public health are moving through Congress. In the House of Representatives, lawmakers are scheduled to consider H.R. 2483, formally known as the SUPPORT for Patients and Communities Reauthorization Act of 2025. This crucial piece of legislation aims to reauthorize and build upon existing programs designed to combat the opioid crisis and support affected communities.
Meanwhile, the Senate is actively considering a House-passed reconciliation bill. This bill has become a focal point of intense partisan debate. Senate Democrats have expressed significant opposition to the measure, particularly focusing on proposed changes to Medicaid and the Affordable Care Act (ACA). Senate Minority Leader Schumer (D-NY) has been a vocal critic of these provisions, arguing they would undermine access to healthcare for millions of Americans.
Concerns about the reconciliation bill are not limited to its direct impact on healthcare programs. Several Republican senators, including Senators Johnson (R-WI), Paul (R-KY), Lee (R-UT), and Scott (R-FL), have raised alarms regarding the bill’s potential impact on future federal deficits, adding another layer of complexity to its passage.
As these legislative debates heat up, the formal process for the FY 2026 appropriations is also set to begin. This marks the start of the annual congressional effort to determine specific funding levels for all federal agencies, including HHS and its components, setting the stage for months of negotiations and political maneuvering over the nation’s spending priorities.
The convergence of steep proposed budget cuts for key health agencies, significant legislative action on critical health policies, and the commencement of the appropriations cycle ensures that healthcare will remain a central and contentious issue on the U.S. political agenda throughout the week and the coming months. The ultimate outcome will have profound implications for public health research, disease prevention, food and drug safety, and federal healthcare programs serving millions.
